bms (bristol-myers squibb) france

What bms (bristol-myers squibb) france does

BMS France is the French operating subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company headquartered in the United States and tracing its origins to the 1887 founding of Bristol-Myers Company and the 1989 merger with Squibb Corporation. The French entity is registered as Bristol-Myers Squibb SAS, headquartered at 3 rue Joseph Monier, 92500 Rueil-Malmaison, and operates as a wholly-owned subsidiary serving the French market. BMS France commercializes over 20 approved prescription medicines across five core therapeutic areas: oncology (OPDIVO, YERVOY, OPDUALAG, ABRAXANE), cardiology (ELIQUIS anticoagulant, CAMZYOS for hypertrophic cardiomyopathy), hematology (REVLIMID, IMNOVID/POMALYST, ABECMA and BREYANZI CAR-T cell therapies, REBLOZYL, INREBIC, ONUREG, VIDAZA, THALIDOMIDE, SPRYCEL), immunology (ORENCIA, SOTYKTU), and virology/transplantation (REYATAZ, BARACLUDE, NULOJIX, KENACORT).

The company's underlying technology stack includes proprietary CAR-T cell therapy manufacturing platforms (ABECMA, BREYANZI), immuno-oncology checkpoint inhibitors targeting PD-1, CTLA-4, and LAG-3, and a diversified small-molecule and biologic portfolio spanning oral, injectable, and intravenous formulations. BMS invests several billion euros annually in research and development at the corporate level, with French operations supporting clinical trial execution, medical information services, and pharmacovigilance. Distribution occurs through hospital pharmacies (EDI ordering code 12A), pharmaceutical wholesalers (EDI code 42Z), and retail pharmacy networks, supported by a 24/7 medical information service accessible via phone, email, and the bmsmedinfo.fr portal. Field-based medical sales representatives (visiteurs médicaux) engage healthcare professionals directly, while strategic partnerships with patient associations, healthcare institutions, and research centers support clinical trials and patient access programs.

The business model is prescription pharmaceutical sales at one-time license transaction level, generating revenue through hospital procurement, wholesale distribution, and retail pharmacy dispensing under French social security reimbursement schemes. The target customer base spans patients with serious diseases (cancer, cardiovascular, hematologic, immunologic, viral conditions), prescribing physicians across multiple specialties, hospitals and hospital pharmacies, and ultimately the French healthcare system as the reimbursement payor. BMS France does not disclose standalone subsidiary revenue or headcount, with financial performance consolidated into the parent company's global reporting.

Name

bms (bristol-myers squibb) france

Legal name

Bristol-Myers Squibb Company

Website

https://bmsfrance.fr

Company type

Public

Founded year

1887

Operating status

Operating

Short description

BMS France is the French subsidiary of Bristol-Myers Squibb (NYSE: BMY), commercializing over 20 prescription biopharmaceuticals across oncology, cardiology, hematology, immunology, and virology to patients, healthcare professionals, and hospitals in France through hospital and pharmacy distribution channels.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Prescription pharmaceuticals
• Oncology medicines
• Biopharmaceutical products
• Cell therapy treatments
• Immunotherapy drugs

Headquarters

HQ city

Rueil-malmaison

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Pharmaceutical Product Sales: BMS generates revenue through the sale of prescription biopharmaceutical medicines across multiple therapeutic areas including oncology, cardiology, hematology, immunology, and virology. Products are distributed through hospital and retail pharmacy channels in France.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Bristol-Myers Squibb France develops, manufactures, and distributes prescription biopharmaceutical medicines across oncology, cardiology, hematology, immunology, virology, and transplantation therapeutic areas. The portfolio includes small-molecule drugs, immunotherapies (checkpoint inhibitors), and advanced CAR-T cell therapies marketed in France through hospital pharmacies, wholesale distributors, and retail pharmacies.

Product overview

Bristol-Myers Squibb France operates as a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines to patients with serious diseases. The company's product portfolio spans five core therapeutic areas: (1) Oncology, featuring immunotherapy treatments OPDIVO, YERVOY, OPDUALAG, and chemotherapy agent ABRAXANE; (2) Hematology, with CAR T-cell therapies ABECMA and BREYANZI, immunomodulatory drugs REVLIMID, IMNOVID, and THALIDOMIDE, and anemia treatments REBLOZYL and INREBIC; (3) Cardiovascular, with anticoagulant ELIQUIS and cardiac therapy CAMZYOS; (4) Immunology, including ORENCIA and novel psoriasis treatment SOTYKTU; and (5) Virology/Transplantation, with HIV treatment REYATAZ, hepatitis B treatment BARACLUDE, and transplant rejection prevention NULOJIX. The portfolio includes both small molecule drugs and advanced cell therapies (CAR-T), delivered through various formulations including oral, injectable, and intravenous administration.

Differentiator

Problem solved

Functional benefit

Products and services

• ELIQUIS (apixaban) Anticoagulant medication for the prevention and treatment of blood clots, prescribed by physicians for cardiovascular patients.
• CAMZYOS (Mavacamten) Cardiac myosin inhibitor for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
• OPDIVO (nivolumab) PD-1 inhibitor immunotherapy for the treatment of various cancers including melanoma, lung cancer, and kidney cancer.
• YERVOY (ipilimumab) CTLA-4 inhibitor immunotherapy used in combination with nivolumab for the treatment of melanoma and other cancers.
• OPDUALAG (nivolumab/relatlimab) Fixed-dose combination immunotherapy combining nivolumab and relatlimab for the treatment of advanced melanoma.
• ABRAXANE (paclitaxel-albumine) Nanoparticle albumin-bound paclitaxel formulation for metastatic breast cancer, pancreatic cancer, and non-small cell lung cancer.
• REVLIMID (lénalidomide) Immunomodulatory drug used for the treatment of multiple myeloma and other hematologic malignancies.
• POMALYST/IMNOVID (pomalidomide) Immunomodulatory drug for the treatment of relapsed and refractory multiple myeloma.
• ABECMA (idecabtagene vicleucel) CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma in adults who have received at least four prior therapies.
• BREYANZI (lisocabtagene maraleucel) CAR T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
• SPRYCEL (dasatinib) Tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia.
• INREBIC (fedratinib) Kinase inhibitor for the treatment of intermediate-2 and high-risk primary or secondary myelofibrosis in adults.
• ONUREG (azacitidine) Nucleoside metabolic inhibitor for the maintenance treatment of adult patients with acute myeloid leukemia.
• VIDAZA (azacitidine) Nucleoside analog for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
• REBLOZYL (luspatercept) Erythroid maturation agent for the treatment of anemia in adult patients with beta-thalassemia and myelodysplastic syndromes.
• THALIDOMIDE BMS Immunomodulatory drug used in combination with dexamethasone for the treatment of multiple myeloma.
• ORENCIA (abatacept) Selective costimulation modulation agent for the treatment of rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis.
• SOTYKTU (deucravacitinib) Tyrosine kinase 2 inhibitor for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
• NULOJIX (bélatacept) Selective costimulation blockade agent for the prevention of acute graft rejection in adult renal transplant recipients.
• BARACLUDE (entecavir) Nucleoside analog for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication.
• REYATAZ (atazanavir) Protease inhibitor for the treatment of HIV-1 infection in combination with other antiretroviral agents.
• KENACORT RETARD (acétonide de triamcinolone) Corticosteroid injection for the treatment of various inflammatory and allergic conditions.

Quantifiable outcome

• BMS invests several billion euros annually in R&D for discovering and developing new medicines

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• TucuviminorStrategic or Co-development PartnerBristol Myers Squibb Spain partnership with Tucuvi to advance cardiomyopathy treatment through technological innovation. This collaboration focuses on improving patient outcomes in cardiovascular disease through digital health solutions and technology partnerships.
• Patient AssociationscoreStrategic or Co-development PartnerBMS partners with patient associations to provide support programs, disease awareness campaigns, and patient education initiatives. These partnerships help address patient needs and improve access to information and support services.
• Healthcare Institutions and Research CenterscoreStrategic or Co-development PartnerBMS collaborates with hospitals, universities, and research institutions for clinical trials, scientific research, and medical education. These partnerships support the development of innovative medicines and advance medical knowledge.
• Pharmaceutical Wholesalers and DistributorscoreChannel Partner/ Reseller/ DistributorBMS distributes products through pharmaceutical wholesale distribution networks (grossistes répartiteurs) to ensure medicines reach hospitals and retail pharmacies across France. EDI systems connect BMS with distributor partners.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Customer concentration

• Xx.com/bmsfrance
• YouTubeyoutube.com/bristolmyerssquibbfrance
• LinkedInlinkedin.com/company/bristol-myers-squibb
• Instagraminstagram.com/bms_france

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about bms (bristol-myers squibb) france